{
    "id": "6020a7391cb411341a00007e",
    "question": "Is Benralizumab effective for Chronic Spontaneous Urticaria?",
    "options": {
        "A": "yes",
        "B": "no"
    },
    "answer": "A",
    "predict": "{\"step_by_step_thinking\": \"To answer this question, we need to evaluate the effectiveness of Benralizumab for Chronic Spontaneous Urticaria (CSU). First, let's review what CSU is and the treatment options available. CSU is a chronic condition characterized by the presence of wheals (hives) that last more than 6 weeks. Treatment options for CSU include H1 and H2 antihistamines, corticosteroids, and immunomodulating agents. Among the latter, monoclonal antibodies targeting IL-5 have shown promise in treating severe asthma and have been explored for CSU as well. Now, let's examine the available options and their effects on CSU.\\n\\nBenralizumab is a monoclonal antibody that targets the \\u03b5 subunit of the IL-5 receptor, which plays a key role in eosinophil activation and survival. Given its mechanism of action, Benralizumab has been investigated as a potential treatment for CSU.\\n\\nAccording to the provided documents, mepolizumab and reslizumab, which target IL-5, have been shown to be effective in preventing exacerbations in asthmatic patients with peripheral eosinophilia. Although the documents do not specifically mention Benralizumab for CSU, its mechanism of action suggests that it could potentially be effective in treating CSU as well.\\n\\nTherefore, based on the available information, the answer to the question is that Benralizumab is likely effective for Chronic Spontaneous Urticaria.\\n\\nAnswer Choice: A\", \"answer_choice\": \"A\"}}",
    "snippets": [
        {
            "id": "InternalMed_Harrison_24939",
            "title": "InternalMed_Harrison",
            "content": "Topical glucocorticoids are of no value, and systemic glucocorticoids are generally avoided in idiopathic, allergen-induced, or physical urticarias due to their long-term toxicity. Systemic glucocorticoids are useful in the management of patients with pressure urticaria, vasculitic urticaria (especially with eosinophil prominence), idiopathic angioedema with or without urticaria, or chronic urticaria that responds poorly to conventional treatment. With persistent vasculitic urticaria, hydroxychloroquine, dapsone, or colchicine may be added to the regimen after hydroxyzine and before or"
        },
        {
            "id": "Immunology_Janeway_3555",
            "title": "Immunology_Janeway",
            "content": "swellings all over the body\u2014a disseminated version of the wheal-and-flare reaction. Although acute urticaria is commonly caused by an IgE-mediated reaction against an allergen, the causes of chronic urticaria, in which the urticarial rash persists or recurs over long periods, remain incompletely defined. Some cases of chronic urticaria are caused by autoantibodies"
        },
        {
            "id": "Pediatrics_Nelson_1870",
            "title": "Pediatrics_Nelson",
            "content": "Avoidance of triggering agents is important in the management of urticaria and angioedema. The mainstay of pharmacologic treatment is H1 antihistamines. Second-generation H1 antihistamines, such as cetirizine, desloratadine, fexofenadine, levocetirizine, and loratadine, are preferred because they have fewer adverse effects. If a second-generation H1 antihistamine, by itself, does not provide adequate relief, the next step is to add a sedating H1 antihistamine at bedtime or H2 antihistamines, such as cimetidine or ranitidine. Tricyclic antidepressants, such as doxepin, exhibit potent activity at both H1 and H2 receptors. Corticosteroids are effective in treating urticaria and angioedema, although adverse effects from long-term use mandate the lowest dose for the shortest time. When urticaria is resistant to treatment, the leukotriene receptor blocker montelukast has been used in several case studies. Other immunomodulating agents, such as cyclosporine, hydroxychloroquine, methotrexate,"
        },
        {
            "id": "InternalMed_Harrison_24940",
            "title": "InternalMed_Harrison",
            "content": "Allergies, Anaphylaxis, and Systemic Mastocytosis 2120 along with systemic glucocorticoids. Cyclosporine can be efficacious for patients with chronic idiopathic or chronic autoimmune urticaria that is severe and poorly responsive to other modalities and/or where a glucocorticoid requirement is excessive. For chronic urticaria induced by autoantibody activation of mast cells and basophils or cold urticaria, monoclonal anti-IgE antibodies such as omalizumab may be considered. The therapy of inborn C1INH deficiency has been simplified by the finding that attenuated androgens correct the biochemical defect and afford prophylactic protection; their efficacy is attributed to production by the normal gene of an amount of functional C1INH sufficient to control the spontaneous activation of C1. The antifibrinolytic agent \u03b5-aminocaproic acid may be used for preoperative prophylaxis but is contraindicated in patients with thrombotic tendencies or ischemia due to arterial atherosclerosis."
        },
        {
            "id": "Pharmacology_Katzung_2123",
            "title": "Pharmacology_Katzung",
            "content": "The addition of omalizumab to standard, guideline-based therapy for asthmatic inner-city children and adolescents in early summer significantly improved overall asthma control, reduced the need for other medications, and nearly eliminated the autumnal peak in exacerbations. Omalizumab has also been proven effective as a treatment for chronic recurrent urticaria (for which the drug is now approved) and for peanut allergy."
        },
        {
            "id": "InternalMed_Harrison_1649",
            "title": "InternalMed_Harrison",
            "content": "Individuals with classic urticaria (\u201chives\u201d) usually have a hypersensitivity reaction without associated fever. In the presence of fever, urticaria-like eruptions are most often due to urticarial vasculitis (Chap. 385). Unlike individual lesions of classic urticaria, which last up to 24 h, these lesions may last 3\u20135 days. Etiologies include serum sickness (often induced by drugs such as penicillins, sulfas, salicylates, or barbiturates), connective-tissue disease (e.g., systemic lupus erythematosus or Sjren\u2019s syndrome), and infection (e.g., with hepatitis B virus, enteroviruses, or parasites). Malignancy, especially lymphoma, may be associated with fever and chronic urticaria (Chap. 72)."
        },
        {
            "id": "Pediatrics_Nelson_1853",
            "title": "Pediatrics_Nelson",
            "content": "Urticaria/angioedema can be classified into three subcategories: acute, chronic, and physical. By definition acute urticaria and angioedema are hives and diffuse swellingthat last less than 6 weeks. Often the history is quite helpfulin eliciting the cause of the acute reaction (Table 81-1). AnIgE mechanism is more commonly found in acute urticariathan in chronic urticaria. Chronic urticaria and angioedemaare characterized by persistence of symptoms beyond 6 weeks(Table 81-2). Some have daily symptoms of hives and swelling, whereas others have intermittent or recurrent episodes.Chronic urticaria can be idiopathic with unknown causal Foods Egg, milk, wheat, peanuts, tree nuts, soy, shellfish, fish, strawberries (direct mast cell degranulation) Medications Suspect all medications, even over-thecounter or homeopathic medications Insect stings Hymenoptera (honeybee, yellow jacket, hornets, wasp, fire ants), biting insects (papular urticaria)"
        },
        {
            "id": "InternalMed_Harrison_24917",
            "title": "InternalMed_Harrison",
            "content": "Theclassification ofurticaria-angioedema presentedin Table 376-1 focuses on the different mechanisms for eliciting clinical disease and can be useful for differential diagnosis; nonetheless, most cases of chronic urticaria are idiopathic. Urticaria and/or angioedema occurring during the appropriate season in patients with seasonal respiratory allergy or as a result of exposure to animals or molds is attributed to inhalation or physical contact with pollens, animal dander, and mold spores, respectively. However, urticaria and angioedema secondary to inhalation are relatively uncommon compared to urticaria and"
        },
        {
            "id": "Pathology_Robbins_5215",
            "title": "Pathology_Robbins",
            "content": "Urticaria typically affects individuals between 20 and 40 years of age, but no age is immune. Individual lesions usually develop and fade within hours, but episodes can persist for days or even months. Lesions range in size and nature from small, pruritic papules to large, edematous, erythematous plaques. They may be localized to a particular part of the body or generalized. In a specific type of urticaria termed pressure urticaria, lesions are found only in areas exposed to pressure (such as the feet or buttocks). Although not life-threatening, severe pruritus and the social embarrassment of urticaria can compromise quality of life. Most cases respond to antihistamines, but more severe, refractory disease may require treatment with leukotriene antagonists, monoclonal antibodies that block the action of IgE, or immunosuppressive drugs."
        },
        {
            "id": "InternalMed_Harrison_4124",
            "title": "InternalMed_Harrison",
            "content": "(Table 72-14) Urticaria (hives) are transient lesions that are composed of a central wheal surrounded by an erythematous halo or flare. Individual lesions are round, oval, or figurate and are often pruritic. Acute and chronic urticaria have a wide variety of allergic etiologies and reflect edema in the dermis. Urticarial lesions can also be seen in patients with mastocytosis (urticaria pigmentosa), hypoor hyperthyroidism, and systemic-onset juvenile idiopathic arthritis (Still\u2019s disease). In both juvenileand adult-onset Still\u2019s disease, the lesions CAuSES of uRTiCARiA AnD AngioEDEMA I. Primary cutaneous disorders A. Acute and chronic urticariaa B. Physical urticaria 1. 2. 3. 4. C. Angioedema (hereditary and acquired)b,c II. A. B. C. D. aA small minority develop anaphylaxis. bAlso systemic. cAcquired angioedema can be idiopathic, associated with a lymphoproliferative disorder, or due to a drug, e.g., angiotensin-converting enzyme (ACE) inhibitors."
        },
        {
            "id": "InternalMed_Harrison_24916",
            "title": "InternalMed_Harrison",
            "content": "Urticaria and angioedema probably occur more frequently than reported because of the evanescent, self-limited nature of such eruptions,whichseldomrequiremedicalattentionwhenlimitedtotheskin. Although persons in any age group may experience acute or chronic urticaria and/or angioedema, these lesions increase in frequency after adolescence, with the highest incidence occurring in persons in the third decade of life; indeed, one survey of college students indicated that 15\u201320% had experienced a pruritic wheal reaction."
        },
        {
            "id": "Pharmacology_Katzung_6187",
            "title": "Pharmacology_Katzung",
            "content": "Omalizumab is an anti-IgE recombinant humanized monoclonal antibody that is approved for the treatment of allergic asthma in adult and adolescent patients whose symptoms are refractory to inhaled corticosteroids (see Chapter 20). The drug is also approved for chronic urticaria. The antibody blocks the binding of IgE to the high-affinity Fc\u03b5 receptor on basophils and mast cells, which suppresses IgE-mediated release of type I allergy mediators such as histamine and leukotrienes. Total serum IgE levels may remain elevated in patients for up to 1 year after administration of omalizumab."
        },
        {
            "id": "Immunology_Janeway_3593",
            "title": "Immunology_Janeway",
            "content": "by exposure to allergens. Omalizumab also appears to act in chronic allergic asthma to reduce IgE-mediated antigen trapping and presentation by dendritic cells, thus preventing the activation of new allergen-specific TH2 cells. Altogether, these actions lead to suppression of the late-phase response to allergen challenge (see Section 14-9). The antibody is administered by subcutaneous injections once every 2 to 4 weeks. This treatment has been shown to be highly effective for patients with chronic urticaria and also appears to be effective in individuals with severe chronic asthma. Of special interest is that in studies of children with moderate to severe asthma who were treated for 4 years with omalizumab, most remained symptom free without any anti-asthma treatment, suggesting that the anti-IgE therapy modified the natural history of the disease."
        },
        {
            "id": "Pharmacology_Katzung_2146",
            "title": "Pharmacology_Katzung",
            "content": "Treatment with omalizumab, the monoclonal humanized anti-IgE antibody, and with any of the monoclonal anti-IL-5 antibodies is reserved for patients with chronic severe asthma inadequately controlled by ICS/LABA treatment. Omalizumab reduces lymphocytic, eosinophilic bronchial inflammation, oral and inhaled corticosteroid dose requirements, and the frequency and severity of exacerbations. It is reserved for patients with demonstrated IgEmediated sensitivity (by positive skin test or radioallergosorbent test [RAST] to common allergens) and an IgE level within a range that can be reduced sufficiently by twice-weekly subcutaneous injection. Other options for treatment of severe asthma uncontrolled by ICS/ LABA therapy, especially if associated with peripheral eosinophilia, are the monoclonal antibodies reviewed earlier\u2014mepolizumab, reslizumab, and benralizumab."
        },
        {
            "id": "InternalMed_Harrison_24908",
            "title": "InternalMed_Harrison",
            "content": "0.25\u20130.5 g IV, are appropriate for urticaria-angioedema and bronchospasm, respectively. Intravenous glucocorticoids, 0.5\u20131 mg/kg of methylprednisolone, are not effective for the acute event but may alleviate later recurrence of bronchospasm, hypotension, or urticaria."
        },
        {
            "id": "Pharmacology_Katzung_2125",
            "title": "Pharmacology_Katzung",
            "content": "Like omalizumab, reslizumab carries a small (0.3%) risk of anaphylaxis, and a period of observation following infusion is recommended. Mepolizumab, although not associated with anaphylaxis, has resulted in reports of hypersensitivity. In addition, reactivation of herpes zoster has been reported in some patients who received mepolizumab. Clinical trials of dupilumab (an antibody directed against the IL-4\u03b1 co-receptor for both IL-4 and IL-13; not yet approved) have shown it to reduce exacerbation frequency and improve measures of asthma control in patients with and without systemic eosinophilia and, further, to markedly reduce the severity of allergic dermatitis."
        },
        {
            "id": "Pediatrics_Nelson_1868",
            "title": "Pediatrics_Nelson",
            "content": "From Zuraw B: Urticaria and angioedema. In Leung DYM, Sampson HA, Geha RS, et al, editors: Pediatric Allergy: Principles and Practice, St Louis, 2003, Mosby, p 580. When these lesions are stroked, they urticate, which is calledthe Darier sign. A rare disorder that should be included in the differential diagnosis of urticaria is Muckle-Wells syndrome. It is an autosomal dominant disorder characterized by episodic urticaria presenting in infancy, with sensorineuraldeafness, amyloidosis, arthralgias, and skeletal abnormalities.Another rare syndrome is Schnitzler syndrome, which is characterized by chronic urticaria, macroglobulinemia, bonepain, anemia, fever, fatigue, and weight loss. Urticarial vasculitis is a small vessel vasculitis with histologic features of aleukocytoclastic response. The main distinguishing feature isthat the lesions last longer than 24 hours, may be tender, andleave behind skin pigmentation. Skin biopsy is required fordefinitive diagnosis."
        },
        {
            "id": "Pediatrics_Nelson_1862",
            "title": "Pediatrics_Nelson",
            "content": "Urticaria and angioedema are common skin conditions affecting 15% to 25% of individuals at some point in their lives. Most cases of urticaria are self-limited, but, for some patients, they are chronic. In approximately 50% of patients, urticaria and angioedema occur together. In the remaining 50%, 40% have urticaria alone and 10% have angioedema alone. The incidence of anaphylaxis in children is unknown. Available @ StudentConsult.com"
        },
        {
            "id": "InternalMed_Harrison_24928",
            "title": "InternalMed_Harrison",
            "content": "induced lesional sites in patients with dermographism, pressure urticaria, vibratory angioedema, light urticaria, and heat urticaria. By ultrastructural analysis, the pattern of mast cell degranulation in cold urticaria resembles an IgE-mediated response with solubilization of granule contents, fusion of the perigranular and cell membranes, and discharge of granule contents, whereas in a dermographic lesion, there is additional superimposed zonal (piecemeal) degranulation. There are several reports of resolution of cold urticaria by treatment with monoclonal anti-human IgE (omalizumab). Elevations of plasma histamine levels with biopsy-proven mast cell degranulation have also been demonstrated with generalized attacks of cholinergic urticaria and exercise-related anaphylaxis precipitated experimentally in subjects exercising on a treadmill while wearing a wet suit; however, only subjects with cholinergic urticaria have a concomitant decrease in pulmonary function."
        },
        {
            "id": "Pharmacology_Katzung_2124",
            "title": "Pharmacology_Katzung",
            "content": "T2 cells secrete IL-5 as a pro-eosinophilic cytokine that results in eosinophilic airway inflammation. Although not central to the mechanisms of asthma in all patients, a substantial proportion of patients with severe asthma have airway and peripheral eosinophilia driven by up-regulation of IL-5-secreting T2 lymphocytes. Two humanized monoclonal antibodies targeting IL-5, mepolizumab and reslizumab, and another targeting the IL-5 receptor, benralizumab, have recently been developed for the treatment of eosinophilic asthma. Clinical trials with these drugs have shown them to be effective in preventing exacerbations in asthmatic patients with peripheral eosinophilia, leading to their approval as add-on, maintenance therapy of severe asthma in patients with an eosinophilic phenotype."
        },
        {
            "id": "First_Aid_Step2_103",
            "title": "First_Aid_Step2",
            "content": "Treat with topical steroids combined with keratolytic agents, tar, or anthralin along with UV therapy, including PUVA. Methotrexate may be used for severe cases. Retinoids (vitamin A derivatives) may also be used. Arthritis should be treated first with NSAIDs and then with methotrexate if necessary. Systemic corticosteroids should be avoided, as tapering can induce psoriatic \ufb02 ares. Recently, biologic agents such as TNF-\u03b1 inhibitors have proven effective in severe psoriatic arthritis and psoriasis. Urticaria is characterized by superficial, intense edema in a localized area. It is usually acute but can also be chronic (lasting > 6 weeks). The condition results from the release of vasoactive substances (histamine, prostaglandins) from mast cells in a type I hypersensitivity response. \u25a0Hives can range in severity from a few itchy bumps to life-threatening anaphylaxis."
        },
        {
            "id": "Pathology_Robbins_5211",
            "title": "Pathology_Robbins",
            "content": "Table 24.1 Thousands of inflammatory dermatoses exist, challenging the diagnostic acumen of even experienced clinicians. In general, acute lesions, defined as days to several weeks in duration, are characterized by inflammation, edema, and sometimes epidermal, vascular, or subcutaneous injury. Acute dermatoses are often marked by infiltrates consisting of mononuclear cells rather than neutrophils, unlike acute inflammatory disorders at most other sites. Some acute lesions may persist, transitioning to a chronic phase, while others are self-limited. Urticaria (\u201chives\u201d) is a common disorder mediated by localized mast cell degranulation, which leads to dermal microvascular hyperpermeability. The resulting erythematous, edematous, and pruritic plaques are termed wheals. In most cases, urticaria stems from an immediate (type 1) hypersensitivity reaction (Chapter 5), in which antigens trigger mast cell degranulation by binding to http://ebooksmedicine.net"
        },
        {
            "id": "InternalMed_Harrison_24915",
            "title": "InternalMed_Harrison",
            "content": "Urticaria and angioedema may appear separately or together as cutaneous manifestations of localized nonpitting edema; a similar process may occur at mucosal surfaces of the upper respiratory or gastrointestinal tract. Urticaria involves only the superficial portion of the dermis, presenting as well-circumscribed wheals with erythematous raised serpiginous borders and blanched centers that may coalesce to become giant wheals. Angioedema is a well-demarcated localized edema involving the deeper layers of the skin, including the subcutaneous tissue, and can also involve the bowel wall. Recurrent episodes of urticaria and/or angioedema of less than 6 weeks\u2019 duration are considered acute, whereas attacks persisting beyond this period are designated chronic."
        },
        {
            "id": "Pediatrics_Nelson_1855",
            "title": "Pediatrics_Nelson",
            "content": "Idiopathic 75%\u201390% of cases 25%\u201350% of adult patients have IgG, anti-IgE, and anti-Fc\u03b5R1 (high-affinity IgE receptor alpha chain) autoantibodies Angioedema Hereditary angioedema (autosomal dominant inherited deficiency of Cl-esterase inhibitor) From Lasley MV, Kennedy MS, Altman LC: Urticaria and angioedema. In Altman LC, Becker JW, Williams PV, editors: Allergy in Primary Care, Philadelphia, 2000, Saunders, p 234. factors; 35% to 40% of chronic urticaria cases have an autoimmune process due to IgG autoantibodies binding directly toIgE or to the IgE receptor. Physical urticaria and angioedemaare characterized by known eliciting external factors that mayinclude pressure, cold, heat, exercise, or exposure to sun or water."
        },
        {
            "id": "First_Aid_Step2_104",
            "title": "First_Aid_Step2",
            "content": "\u25a0Hives can range in severity from a few itchy bumps to life-threatening anaphylaxis. The typical lesion is an elevated papule or plaque that is reddish or white and variable in size. Lesions are widespread and last a few hours. In severe allergic reactions, extracutaneous manifestations can include tongue swelling, angioedema (deeper, more diffuse swelling), asthma, GI symptoms, joint swelling, and fever. Acute urticaria is a response to a trigger that may be a food, drug, virus, insect bite, or physical stimulus. Chronic urticaria is usually idiopathic. Diagnosed by clinical impression and patient report. Biopsy demonstrates perivascular edema. It can often be difficult to determine the cause. Treat with systemic antihistamines. Topical medications are of no benefit."
        },
        {
            "id": "First_Aid_Step1_797",
            "title": "First_Aid_Step1",
            "content": "P-450. Blocks actions of adenosine. Muscarinic Chromones Cromolyn\u2014prevents mast cell degranulation. antagonists Prevents acute asthma symptoms. Rarely used. Anti-IL-5 monoclonal Prevents eosinophil differentiation, maturation, therapy activation, and survival mediated by IL-5 Early response: Late response: stimulation. For maintenance therapy in severe eosinophilic asthma. Mepolizumab, reslizumab\u2014against IL-5. Benralizumab\u2014against IL-5 receptor \u03b1. \u201cStudy without thought is vain: thought without study is dangerous.\u201d \u201cIt is better, of course, to know useless things than to know nothing.\u201d \u201cFor every complex problem there is an answer that is clear, simple, and wrong.\u201d \u2014H. L. Mencken The following tables represent a collection of high-yield associations between diseases and their clinical findings, treatments, and key associations. They can be quickly reviewed in the days before the exam."
        },
        {
            "id": "InternalMed_Harrison_4129",
            "title": "InternalMed_Harrison",
            "content": "Urticarial vasculitis is an immune complex disease that may be confused with simple urticaria. In contrast to simple urticaria, individual lesions tend to last longer than 24 h and usually develop central petechiae that can be observed even after the urticarial phase has resolved. The patient may also complain of burning rather than pruritus. On biopsy, there is a leukocytoclastic vasculitis of the small dermal blood vessels. Although many cases of urticarial vasculitis are idiopathic in origin, it can be a reflection of an underlying systemic illness such as lupus erythematosus, Sj\u00f6gren\u2019s syndrome, or hereditary complement deficiency. There is a spectrum of urticarial vasculitis that ranges from purely cutaneous to multisystem involvement. The most common systemic signs and symptoms are arthralgias and/or arthritis, nephritis, and crampy abdominal pain, with asthma and chronic obstructive lung disease seen less often. Hypocomplementemia occurs in oneto two-thirds of patients, even in"
        },
        {
            "id": "InternalMed_Harrison_4300",
            "title": "InternalMed_Harrison",
            "content": "The treatment of urticaria or angioedema depends on the severity of the reaction. In severe cases with respiratory or cardiovascular compromise, epinephrine is the mainstay of therapy, but its effect is reduced in patients using beta blockers. Treatment with intravenous systemic glucocorticoids is helpful. For patients with urticaria without symptoms of angioedema or anaphylaxis, drug withdrawal and oral antihistamines are usually sufficient. Future drug avoidance is recommended; rechallenge, especially in individuals with severe reactions, should only occur in an intensive care setting. Anaphylactoid Reactions Vancomycin is associated with red man syndrome, a histamine-related anaphylactoid reaction characterized by flushing, diffuse maculopapular eruption, and hypotension. In rare cases, cardiac arrest may be associated with rapid IV infusion of the medication."
        },
        {
            "id": "InternalMed_Harrison_24933",
            "title": "InternalMed_Harrison",
            "content": "The classification of urticarial and angioedematous states presented in Table 376-1 in terms of possible mechanisms necessarily includes some differential diagnostic points. Hypocomplementemia is not observed in IgE-mediated mast cell disease and may reflect either an acquired abnormality generally attributed to the formation of immune complexes or a genetic or acquired deficiency of C1INH. Chronic recurrent urticaria, generally in females, associated with arthralgias, an elevated sedimentation rate, and normo-or hypocomplementemia suggests an underlying cutaneous necrotizing angiitis. Vasculitic urti-2119 cariatypicallypersistslongerthan 72h,whereasconventionalurticaria often has a duration of 12\u201336 h. Confirmation depends on a biopsy that reveals cellular infiltration, nuclear debris, and fibrinoid necrosis of the venules. The same pathobiologic process accounts for the urticariainassociationwith suchdiseasesassystemiclupus erythematosus or viral hepatitis with or without associated"
        },
        {
            "id": "InternalMed_Harrison_30996",
            "title": "InternalMed_Harrison",
            "content": "Natalizumab, 300 mg, is administered by IV infusion each month. Treatment with natalizumab is, in general, well tolerated. A small percentage (<10%) of patients experience hypersensitivity reactions (including anaphylaxis), and \u223c6% develop neutralizing antibodies to the molecule (only half of which persist)."
        },
        {
            "id": "InternalMed_Harrison_24929",
            "title": "InternalMed_Harrison",
            "content": "Up to 40% of patients with chronic urticaria have an autoimmune cause for their disease including autoantibodies to IgE (5\u201310%) or, more commonly, to the \u03b1 chain of Fc\u03b5RI (35\u201345%). In these patients, autologous serum injected into their own skin can induce a wheal-and-flare reaction involving mast cell activation. The presence of these antibodies can alsoberecognized by their capacityto releasehistamine or induce activation markers such as CD63 or CD203 on basophils. An association with antibodies to microsomal peroxidase and/or thyroglobulin has been observed often with clinically significant Hashimoto\u2019s thyroiditis. In vitro studies reveal that these autoantibodies can mediate basophil degranulation with enhancement by serum as a source of the anaphylatoxic fragment, C5a."
        },
        {
            "id": "InternalMed_Harrison_8850",
            "title": "InternalMed_Harrison",
            "content": "Both indolent and aggressive SM patients might experience mast cell mediator release symptoms, which are usually managed by both H1 and H2 histamine receptor blockers as well as cromolyn sodium. In addition, patients with propensity to vasodilatory shock should wear a medical alert bracelet and carry an Epi-Pen self-injector for self-administration of subcutaneous epinephrine. Urticaria pigmentosa shows variable response to both topical and systemic glucocorticoid therapy. Cytoreductive therapy is not recommended for indolent SM. In aggressive SM, either interferon \u03b1 or cladribine is considered first-line therapy and benefits the majority of patients. In contrast, imatinib is ineffective in the treatment of PDGFR-unmutated SM."
        }
    ],
    "scores": [
        0.038439289490668896,
        0.03525818841352822,
        0.034855502081479875,
        0.03426614850834196,
        0.03382786658161086,
        0.033336078666267345,
        0.032596211023322844,
        0.03195693195693196,
        0.03167942315978012,
        0.03162358616697554,
        0.031163713953187636,
        0.02928828654161264,
        0.028336740101445983,
        0.028317012054834115,
        0.027117670488408657,
        0.025013106057853514,
        0.024134248665141113,
        0.024052471872923472,
        0.02403596475086385,
        0.023517557493216722,
        0.02280711482419336,
        0.022317113186296682,
        0.021390921960181924,
        0.02135548790799932,
        0.020974849754528527,
        0.02094328390156456,
        0.020496405685437674,
        0.020327532601596383,
        0.01893367417711987,
        0.018791800491214813,
        0.018170288390210974,
        0.016842847075405214
    ]
}